Tamoxifen Prophylaxis: Prevention is Better Than Cure — Prevention is Cure?
Part of the
book series (ESO MONOGRAPHS)
The treatment of advanced breast cancer with surgery, hormonal modalities, radiotherapy and chemotherapy has met with palliation in the face of relentlessy progressive disease. The remarkable successes observed with chemotherapy in testicular carcinoma, Hodgkin’s disease or childhood leukaemias are rarely, if ever, observed in advanced breast cancer. Often the gains made are at a price. Discomfort and side effects are the patients’ constant companions during rigorous chemotherapy regimens. Unfortunately, objective and complete responses invariably turn to rapidly growing drug-and radiation-resistant disease.
KeywordsPlacebo Osteoporosis Tamoxifen Progesterone Oestradiol
Clark CL and Satyaswaroop PG: Photoaffinity labeling of the progesterone receptor from human endometrial carcinoma. Cancer Res 1985 (45): 5417–5420Google Scholar
Cuzick J, Wang DY and Bulbrook RD: The prevention of breast cancer. Lancet 1986 (1): 83–86PubMedCrossRefGoogle Scholar
Groom GV and Griffiths K: Effect of the antioestrogen tamoxifen on plasma levels of luteinizing hormone, follicle stimulating hormone, prolactin, and oestradiol and progesterone in normal pre-menopausal women. J Endocrinology 1976 (70): 421–428CrossRefGoogle Scholar
Jordan VC: Effect of tamoxifen (ICI 46,47) on initn and growth of DMBA-induced rat mammary carcinomata. Europ J Cancer 1976 (12): 419–424CrossRefGoogle Scholar
Jordan VC: Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antioestrogen: problems and potential for future clinical applications. Breast Cancer Res Treat 1983 (3): 73–86CrossRefGoogle Scholar
Sherman BM, Chapler F, Crickard K and Wycoff D: Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women. J Clin Invest 1979 (64): 318–404CrossRefGoogle Scholar
© Springer-Verlag Berlin Heidelberg 1986